Patterns of Recurrence after Neoadjuvant Therapy in Early Breast Cancer, according to the Residual Cancer Burden Index and Reductions in Neoadjuvant Treatment Intensity
Authors:
- Christoph SuppanCSChristoph Suppan
- Florian PoschFPFlorian Posch
- Hannah Deborah MuellerHMHannah Deborah Mueller
- Nina MischitzNMNina Mischitz
- Daniel SteinerDSDaniel Steiner
- Eva Valentina KlockerEKEva Valentina Klocker
- Lisa SetaffyLSLisa Setaffy
- Ute BargfriederUBUte Bargfrieder
- Robert HammerRHRobert Hammer
- Hubert HauserHHHubert Hauser
- Philipp J. JostPJPhilipp J. Jost
- Nadia DandachiNDNadia Dandachi
Open Access
Abstract
Background: The prognostic performance of the residual cancer burden (RCB) score is a promising tool for breast cancer patients undergoing neoadjuvant therapy. We independently evaluated the prognostic value of RCB scores in an extended validation cohort. Additionally, we analyzed the association between chemotherapy dose reduction and RCB scores. Methods: In this extended validation study, 367 breast cancer patients with available RCB scores were followed up for recurrence-free survival (RFS), distant disease-free survival (DDFS), and overall survival (OS). We also computed standardized cumulative doses of anthracyclines and taxanes (A/Ts) to investigate a potential interaction between neoadjuvant chemotherapy dose reduction and RCB scores. Results: Higher RCB scores were consistently associated with adverse clinical outcomes across different molecular subtypes (HR for RFS = 1.60, 95% CI 1.33–1.93, p < 0.0001; HR for DDFS = 1.70, 95% CI 1.39–2.05, p < 0.0001; HR for OS = 1.67, 95% CI 1.34–2.08, p < 0.0001). The adverse impact prevailed throughout 5 years of follow-up, with a peak for relapse risk between 1–2 years after surgery. Clinical outcomes of patients with RCB class 1 did not differ substantially at 5 years compared to RCB class 0. A total of 180 patients (49.1%) underwent dose reduction of neoadjuvant A/T chemotherapy. We observed a statistically significant interaction between dose reduction and higher RCB scores (interaction p-value = 0.042). Conclusion: Our results confirm RCB score as a prognostic marker for RFS, DDFS, and OS independent of the molecular subtype. Importantly, we show that lower doses of cumulative neoadjuvant A/T were associated with higher RCB scores in patients who required a dose reduction.Keywords
This publication has 34 references indexed in Scilit:
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trialThe Lancet, 2013
- Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trialsThe Lancet, 2012
- Long-Term Benefit of High-Dose Epirubicin in Adjuvant Chemotherapy for Node-Positive Breast Cancer: 15-Year Efficacy Results of the Belgian Multicentre StudyJournal of Clinical Oncology, 2009
- Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patientsBreast Cancer Research and Treatment, 2008
- Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant ChemotherapyJournal of Clinical Oncology, 2007
- Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP SystemJournal of Clinical Oncology, 2007
- Dose and schedule as determinants of outcomes in chemotherapy for breast cancerSeminars in Oncology, 2004
- Incidence and Predictors of Low Dose-Intensity in Adjuvant Breast Cancer Chemotherapy: A Nationwide Study of Community PracticesJournal of Clinical Oncology, 2003
- Flexible parametric proportional‐hazards and proportional‐odds models for censored survival data, with application to prognostic modelling and estimation of treatment effectsStatistics in Medicine, 2002
- A note on quantifying follow-up in studies of failure timeControlled Clinical Trials, 1996